Polymer-based nanoparticles for chemo/gene-therapy: Evaluation its therapeutic efficacy and toxicity against colorectal carcinoma

Chen, Yan; Li, Ningxi; Xu, Bei; Wu, Min; Yan, Xiaoyan; Zhong, Lijun; Cai, Hong; Wang, Ting; Wang, Qiuju; Long, Fangyi; Ji, Gang; Xiao, Hongtao

doi:10.1016/j.biopha.2019.109257

Cited by 26 publications

(13 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Excessive ROS in cells can destroy proteins, DNA, phospholipids, and other biological macromolecules. The generation of ROS is one main anticancer mechanism of radiotherapy and several therapeutic agents [ 1 , 37 – 39 ]. Therefore, it is of great clinical and theoretical significance to measure the effect of NPs on intracellular ROS production.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Preparation, Biosafety, and Cytotoxicity Studies of a Newly Tumor-Microenvironment-Responsive Biodegradable Mesoporous Silica Nanosystem Based on Multimodal and Synergistic Treatment

Zhang

et al. 2020

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Patients with triple negative breast cancer (TNBC) often suffer relapse, and clinical improvements offered by radiotherapy and chemotherapy are modest. Although targeted therapy and immunotherapy have been a topic of significant research in recent years, scientific developments have not yet translated to significant improvements for patients with TNBC. In view of these current clinical treatment shortcomings, we designed a silica nanosystem (SNS) with Nano-Ag as the core and a complex of MnO2 and doxorubicin (Dox) as the surrounding mesoporous silica shell. This system was coated with anti-PD-L1 to target the PD-L1 receptor, which is highly expressed on the surface of tumor cells. MnO2 itself has been shown to act as chemodynamic therapy (CDT), and Dox is cytotoxic. Thus, the full SNS system presents a multimodal, potentially synergistic strategy for the treatment of TNBC. Given potential interest in the clinical translation of SNS, the biological safety and antitumor activity of SNS were evaluated in a series of studies that included physicochemical characterization, particle stability, blood compatibility, and cytotoxicity. We found that the particle size and zeta potential of SNS were 94.6 nm and -22.1 mV, respectively. Ultraviolet spectrum analysis showed that Nano-Ag, Dox, and MnO2 were successfully loaded into SNS, and the drug loading ratio of Dox was about 10.2%. Stability studies found that the particle size of SNS did not change in different solutions. Hemolysis tests showed that SNS, at levels far exceeding the anticipated physiologic concentrations, did not induce red blood cell lysis. Further in vitro and in vivo experiments found that SNS did not activate platelets or cause coagulopathy and had no significant effects on the total number of blood cells or hepatorenal function. Cytotoxicity experiments suggested that SNS significantly inhibited the growth of tumor cells by damaging cell membranes, increasing intracellular ROS levels, inhibiting the release of TGF-β1 cytokines by macrophages, and inhibiting intracellular protein synthesis. In general, SNS appeared to have favorable biosafety and antitumor effects and may represent an attractive new therapeutic approach for the treatment of TNBC.

show abstract

Section: Resultsmentioning

confidence: 99%

“…The polypeptide IL-1 β is mainly produced by monocytes and macrophages and contributes to inflammation that can result in fever. However, in the tumor microenvironment, it can cause tumor growth and metastasis [ 2 , 39 ]. TGF- β 1 is mainly expressed by endothelial cells, blood cells, connective tissue cells, and epithelial cells.…”

Section: Resultsmentioning

confidence: 99%

Preparation, Biosafety, and Cytotoxicity Studies of a Newly Tumor-Microenvironment-Responsive Biodegradable Mesoporous Silica Nanosystem Based on Multimodal and Synergistic Treatment

Zhang

et al. 2020

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

show abstract

“…PEDF is a retinoprotective protein that naturally occurs in the eye and is present in the aqueous humor of humans [76]; 2. PEDF is nontoxic [77]; 3. PEDF is multimodal and possesses neurotrophic [27], antiangiogenic [55], anti-inflammatory [78], antioxidant properties [79,80], all of which are beneficial for the treatment of several multifactorial retinal diseases; 4.…”

Section: Discussionmentioning

confidence: 99%

Delivery Systems of Retinoprotective Proteins in the Retina

Rebustini¹,

Bernardo-Colón²,

Nalvarte³

et al. 2021

IJMS

View full text Add to dashboard Cite

Retinoprotective proteins play important roles for retinal tissue integrity. They can directly affect the function and the survival of photoreceptors, and/or indirectly target the retinal pigment epithelium (RPE) and endothelial cells that support these tissues. Retinoprotective proteins are used in basic, translational and in clinical studies to prevent and treat human retinal degenerative disorders. In this review, we provide an overview of proteins that protect the retina and focus on pigment epithelium-derived factor (PEDF), and its effects on photoreceptors, RPE cells, and endothelial cells. We also discuss delivery systems such as pharmacologic and genetic administration of proteins to achieve photoreceptor survival and retinal tissue integrity.

show abstract

“…Furthermore, PEDF has demonstrable efficacy in reducing tumour growth, metastasis, and treatment resistance in sex hormone-responsive tumours, which may be due to PEDF interactions with inflammatory and sex hormone signalling pathways in tumour cells. Across a wide range of cancers, PEDF has been shown to be efficacious as an adjuvant therapy in preclinical studies in sex hormone-responsive cancers [17,33,34], as well as cancers arising in other tissues [60][61][62][63], providing the rationale to consider evaluating this serpin in the clinical setting. There is a complex interplay between sex hormones and the cells and acellular structures of the TME.…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

Pigment Epithelium-Derived Factor and Sex Hormone-Responsive Cancers

Brook

Dass

et al. 2020

Cancers

View full text Add to dashboard Cite

Oestrogens and androgens play important roles in normal and cancerous tissue and have been shown to negatively regulate pigment epithelium-derived factor (PEDF) expression in sex hormone-responsive tumours. PEDF suppresses tumour growth and its downregulation by oestrogen is implicated in tumorigenesis, metastasis, and progression. PEDF expression is reduced in cancerous tissue of the prostate, breast, ovary, and endometrium compared to their normal tissue counterparts, with a link between PEDF downregulation and sex hormone signalling observed in pre-clinical studies. PEDF reduces growth and metastasis of tumour cells by promoting apoptosis, inhibiting angiogenesis, increasing adhesion, and reducing migration. PEDF may also prevent treatment resistance in some cancers by downregulating oestrogen receptor signalling. By interacting with components of the tumour microenvironment, PEDF counteracts the proliferative and immunosuppressive effects of oestrogens, to ultimately reduce tumorigenesis and metastasis. In this review, we focus on sex hormone regulation of PEDF’s anti-tumour action in sex hormone-responsive tumours.

show abstract

Polymer-based nanoparticles for chemo/gene-therapy: Evaluation its therapeutic efficacy and toxicity against colorectal carcinoma

Cited by 26 publications

References 51 publications

Preparation, Biosafety, and Cytotoxicity Studies of a Newly Tumor-Microenvironment-Responsive Biodegradable Mesoporous Silica Nanosystem Based on Multimodal and Synergistic Treatment

Preparation, Biosafety, and Cytotoxicity Studies of a Newly Tumor-Microenvironment-Responsive Biodegradable Mesoporous Silica Nanosystem Based on Multimodal and Synergistic Treatment

Delivery Systems of Retinoprotective Proteins in the Retina

Pigment Epithelium-Derived Factor and Sex Hormone-Responsive Cancers

Contact Info

Product

Resources

About